Aim: The aim of this review is to present an overview of the management of toxicities commonly seen in immunotherapy in patients with non-small cell lung cancer. Methods: “non-small cell lung cancer” OR “NSCLC” AND “PD-1” OR “PD-L1” AND from PubMed, Google Scholar, Web of Science databases to identify common toxicities based on the results of studies with patients with non-small cell lung cancer. A search was made with the keywords “retrospective”. Findings: A total of 12 retrospective studies with full texts in English were analyzed. According to the results of the study, it was found that toxicities such as skin reactions, pneumonitis, diarrhea, endocrine disorders, hepatitis, renal toxicity, neurotoxicity and atralgis were developed. Conclusions: In patients with non-small cell lung cancer receiving immunotherapy, it is important to detect toxicities in the early period so that the treatment continues without disruption. Oncology nurses have important roles in the prevent and early detection of toxicities, the education of the patient and their family, and the morning and evaluation of toxicity symptoms.
Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer
